News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The company expects that this development could improve the strength of its application to the FDA for new drug approval
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Subscribe To Our Newsletter & Stay Updated
